Literature DB >> 21815936

Decompressive surgery in combination with preoperative transcatheter arterial embolization: successful improvement of ambulatory function in renal cell carcinoma patients with metastatic extradural spinal cord compression.

Hiroko Suzuki1, Tsunenori Kondo, Ryohei Kuwatsuru, Keiji Wada, Motoya Kubota, Hirohito Kobayashi, Junpei Iizuka, Eri Ikezawa, Toshio Takagi, Kazunari Tanabe.   

Abstract

We analyzed the results of direct decompressive surgery plus stabilization of the vertebrae involved (DDSS) in six non-ambulatory patients with metastatic extradural spinal cord compression (MESCC) due to renal cell carcinoma (RCC). Transcatheter arterial embolization (TAE) was performed prior to surgery to reduce intraoperative blood loss. Radiotherapy and systemic therapy, including cytokine or targeted therapy and zoledronic acid, were added to the surgery. The DDSS procedure was performed successfully in all patients, with an estimated mean blood loss of 1726 mL. After surgery, all patients regained ambulatory function within 2 months. Patients were ambulatory with the use of assisting apparatus for 4-29 months (median 10.5 months). Median overall survival time after surgery was 15 months (range 4-38 months). In conclusion, DDSS with preoperative TAE can be performed safely and significantly improves the ambulatory function of non-ambulatory RCC patients with MESCC.
© 2011 The Japanese Urological Association.

Entities:  

Mesh:

Year:  2011        PMID: 21815936     DOI: 10.1111/j.1442-2042.2011.02822.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  2 in total

1.  Assessing Vascularity of Osseous Spinal Metastases with Dual-Energy CT-DSA: A Pilot Study Compared with Catheter Angiography.

Authors:  Y-C Huang; F-Y Tsuang; C-W Lee; C-Y Wu; Y-H Lin
Journal:  AJNR Am J Neuroradiol       Date:  2019-04-04       Impact factor: 3.825

Review 2.  Interventional management of vertebral body metastases.

Authors:  Ethan A Prince; Sun Ho Ahn
Journal:  Semin Intervent Radiol       Date:  2013-09       Impact factor: 1.513

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.